Provention Bio Inc

NASDAQ:PRVB   4:00:00 PM EDT
8.93
-0.01 (-0.11%)
6:07:14 PM EDT: $9.00 +0.07 (+0.78%)
Products

Provention Bio Inc's TZIELD (Teplizumab-Mzwv) Approved By FDA

Published: 11/17/2022 23:35 GMT
Provention Bio Inc (PRVB) - Tzield™ (teplizumab-mzwv) Approved by FDA As the First and Only Treatment Indicated to Delay the Onset of Stage 3 Type 1 Diabetes (t1d) in Adult and Pediatric Patients Aged 8 Years and Older With Stage 2 T1d.
Tzield™ (teplizumab-mzwv) Approved by FDA As First and Only Treatment Indicated to Delay Onset of Stage 3 Type 1 Diabetes (t1d) in Adult and Pediatric Patients Aged 8 Years and Older With Stage 2 T1d.